Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Abbott (ABT) Confirms Capacity to Support MCS Devices Demand

By Zacks Investment ResearchStock MarketsJun 08, 2021 07:11AM ET
Abbott (ABT) Confirms Capacity to Support MCS Devices Demand
By Zacks Investment Research   |  Jun 08, 2021 07:11AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Abbott Laboratories (NYSE:ABT) ABT recently confirmed that it has adequate capacity and supply to support the expanded use of HeartMate3 heart pump to meet the rising demand for mechanical circulatory support (MCS) devices for the effective treatment of advanced heart failure. This announcement came on the heels of Medtronic (NYSE:MDT)’s MDT last week’s decision to discontinue the global distribution and sale of Medtronic’s competitive product HeartWare ventricular assist device (HVAD).

Abbott’s HearMate 3 thus is expected to meet the excess demand that has been created due to the sudden discontinuation of Medtronic’s HVAD.

In addition, Abbott is working with physicians and health systems to ensure supply of left ventricular assist devices (LVADs) as well as training and education for physicians offering Abbott's HeartMate 3 to patients.

Abbott is expected to strengthen its electrophysiology and heart failure business and expand its customer base globally with adequate capacity and supply to meet the growing demand.

More on HeartMate 3

Abbott’s HeartMate 3 heart pump is a small, implantable mechanical circulatory support device for patients with advanced heart failure in need of either short or long-term support awaiting a heart transplant or who are not eligible for heart transplantation.

In a recent study published in the Annals of Thoracic Surgery regarding the risk of adjusted and propensity matched patients supported with the HeartMate 3 demonstrated that actuarial survival rates were 87% at one year and 84% at two years.

More in the News

Per Abbott’s management, life-savings results has been seen in patients treated with mechanical circulatory support devices and ensuring continued access to these devices is important for patients. Abbott is working to make sure that physicians have the support and training as they adopt HeartMate 3 to enhance outcomes for advanced heart failure patients.

Zacks Investment Research
Zacks Investment Research

Further, left ventricular assist devices (LVADs) remain a vital option for patients with advanced heart failure, either awaiting a heart transplant or not eligible for transplantation which can extend patients’ lives and restore quality of life. Abbott's HeartMate 3 heart pump is available to support physicians and patients globally in markets where the technology has been approved for use.

Recent Developments

In May 2021, Abbott announced a new trial focused on improving treatment for people simultaneously suffering from both atrial fibrillation (AFib) and heart failure. Notably, the trial will make use of Abbott’s technology, including cardiac ablation and sensors to monitor for both pulmonary artery pressure and abnormal heartbeats. The first-of-its-kind trial intends to offer new insights into more effective treatment for patients with AFib and heart failure -- a complex combination that has historically presented significant challenges to physicians.

In April 2021, Abbott announced the receipt of CE Mark for TriClip Transcatheter Tricuspid Valve Repair System -- the first-of-its-kind minimally invasive tricuspid heart valve repair device to treat tricuspid (TR) regurgitation available in Europe. Notably, the clip-based therapy called TriClip G4 is a non-surgical heart valve repair system designed particularly to treat TR, or a leaky tricuspid valve.

Industry Prospects

Per a report by MARKETSANDMARKETS, the global electrophysiology market is projected to reach $10.6 billion by 2025 from $6.8 billion in 2020, at a CAGR of 9.1%. Rising incidence of heart failure and cardiac arrest cases, attributed to lifestyle habits such as smoking and excessive alcohol consumption, are the major factors driving the market.

Price Performance

Shares of the company have gained 21.9% in a year’s time compared with the industry’s 11.1% rise.

Zacks Rank and Key Picks

Currently, the company carries a Zacks Rank #4 (Sell).

A few better-ranked stocks from the broader medical space are Envista Holdings (NYSE:NVST) Corporation NVST and IDEXX Laboratories, Inc. IDXX, each carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank (Strong Buy) stocks here.

Envista Holdings has an estimated long-term earnings growth rate of 26%.

IDEXX Laboratories has a projected long-term earnings growth rate of 20%.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.

Click here for the 4 trades >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Medtronic PLC (MDT): Free Stock Analysis Report

Abbott Laboratories (ABT): Free Stock Analysis Report

IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report

Envista Holdings Corporation (NVST): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research
Abbott (ABT) Confirms Capacity to Support MCS Devices Demand

Related Articles

Blake Morrow
Chart Of The Day: IWM By Blake Morrow - Aug 04, 2021 2

"Why is this a big deal?" With the S&P 500 almost at all time highs once again, we have to acknowledge the underperformance of this index. We are under the assumption that the SPX...

Abbott (ABT) Confirms Capacity to Support MCS Devices Demand

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email